
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio is a promising company in the gene therapy space, backed by a robust pipeline of 13 programs, strong biomarker data, and promising preclinical studies showing a correlation between biomarker data and clinical benefit. However, the recent out-licensing of two lead programs and the challenging financing environment in the biotech industry may pose risks to the company's development plans. This may impact the ability to move their lead program, PBFT02, into a confirmatory trial in the near term.
Bears say
Passage Bio is facing significant regulatory hurdles with their lead program PBFT02 for frontotemporal dementia (FTD), as seen with the recent discontinuation of a similar program by Eli Lilly. This could result in a large investment for Pharmas and potentially hinder the development and advancement of their pipeline. Additionally, the company's total cash of $46.3M and projected cash per share at YE26 raises concerns about future financing and their ability to sustain operations. This, combined with the general risks faced by the biotech industry, leads to a negative outlook on Passage Bio's stock.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares